| Study Presented at ASCO Shows Encouraging Preliminary Results for ...
VANCOUVER and CARLSBAD, CA, June 2 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. today announced preliminary data from a Phase II clinical trial of OGX-011 in combination with docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC). Data were presented by Dr. Kim Chi, Study Chair and a medical oncologist at BC Cancer Agency - Vancouver Centre, representing the National Cancer Institute of Canada - Clinical Trials Group at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Eighty-one patients with metastatic or locally recurrent prostate cancer refractory to hormone therapy were randomized to one of two treatment arms to receive either 640 mg OGX-011 per week in combination with docetaxel and prednisone or docetaxel and prednisone alone.
Canine Cancer Cure - Human Benefit UK Symposium - Effort to Cure ...
LONDON and DENVER, June 29 /PRNewswire/ -- On July 12, a one-day symposium, hosted by the Royal Veterinary College and Morris Animal Foundation, will address the number one cause of death in dogs over the age of two -- cancer -- as well as "translational" cancer treatment research, where the same treatments being developed to help dogs suffering from cancer are being successfully applied to humans, especially children. This is the single most intensive, dedicated event related to this subject ever undertaken in the United Kingdom. U.S.-based, Morris Animal Foundation (MAF) will announce its Cure Canine Cancer Campaign to the United Kingdom. One in four dogs in the UK and worldwide die of cancer; many more suffer its devastating effects. "With canine (comparative) cancer research being a major part of RVC's future Clinical Research Strategy and looking to help coordinate other critical cancer research efforts in the UK and worldwide, we are excited to be host of this very important and valuable MAF cancer research symposium," says Professor Jonathan Elliott, vice principal -- research, Royal Veterinary College.
Antwerp radiotherapy centre chooses TomoTherapy cancer treatment ...
Madison, Wis., USA. The new University Radiotherapy Centre of Antwerp has chosen the TomoTherapy HiArt treatment system for providing radiation therapy, and the Centre will serve as a European training facility for TomoTherapy Incorporated (NASDAQ: TTPY). Hospitals participating in the Centre include University Hospital Antwerp and the Antwerp City Hospital Network. Two HiArt treatment systems have been installed on-site at University Hospital Antwerp. Through the University Radiotherapy Center, both member hospitals will use HiArt treatment systems to treat cancer patients with advanced image-guided, intensity-modulated radiation therapy (IG/IMRT). And, through collaboration with TomoTherapy, the machines will also be available for training physicians, hospital staff and TomoTherapy employees while still providing uninterrupted patient care.
|
